Emergent BioSolutions Inc.Emergent BioSolutions Inc.Emergent BioSolutions Inc.

Emergent BioSolutions Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪320.93 M‬CHF
2.073CHF
‪−173.10 M‬CHF
‪947.80 M‬CHF
‪51.05 M‬
Beta (1Y)
2.57
Employees (FY)
900
Change (1Y)
−700 −43.75%
Revenue / Employee (1Y)
‪1.05 M‬CHF
Net income / Employee (1Y)
‪−192.34 K‬CHF

About Emergent BioSolutions Inc.


CEO
Joseph C. Papa
Headquarters
Gaithersburg
Founded
1998
ISIN
US29089Q1058
FIGI
BBG00LVD90Z2
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Check out other big names from the same industry as ER4.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ER4 is 7.511 CHF — it has increased by 31.40% in the past 24 hours. Watch Emergent BioSolutions Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange Emergent BioSolutions Inc. stocks are traded under the ticker ER4.
We've gathered analysts' opinions on Emergent BioSolutions Inc. future price: according to them, ER4 price has a max estimate of 12.23 CHF and a min estimate of 9.78 CHF. Watch ER4 chart and read a more detailed Emergent BioSolutions Inc. stock forecast: see what analysts think of Emergent BioSolutions Inc. and suggest that you do with its stocks.
ER4 reached its all-time high on Aug 31, 2021 with the price of 58.487 CHF, and its all-time low was 1.899 CHF and was reached on Apr 22, 2024. View more price dynamics on ER4 chart.
See other stocks reaching their highest and lowest prices.
ER4 stock is 23.90% volatile and has beta coefficient of 2.57. Track Emergent BioSolutions Inc. stock price on the chart and check out the list of the most volatile stocks — is Emergent BioSolutions Inc. there?
Today Emergent BioSolutions Inc. has the market capitalization of ‪320.08 M‬, it has increased by 7.42% over the last week.
Yes, you can track Emergent BioSolutions Inc. financials in yearly and quarterly reports right on TradingView.
Emergent BioSolutions Inc. is going to release the next earnings report on Nov 5, 2025. Keep track of upcoming events with our Earnings Calendar.
ER4 earnings for the last quarter are 0.13 CHF per share, whereas the estimation was −0.33 CHF resulting in a 138.71% surprise. The estimated earnings for the next quarter are 0.04 CHF per share. See more details about Emergent BioSolutions Inc. earnings.
Emergent BioSolutions Inc. revenue for the last quarter amounts to ‪111.79 M‬ CHF, despite the estimated figure of ‪116.13 M‬ CHF. In the next quarter, revenue is expected to reach ‪161.63 M‬ CHF.
ER4 net income for the last quarter is ‪−9.52 M‬ CHF, while the quarter before that showed ‪60.20 M‬ CHF of net income which accounts for −115.82% change. Track more Emergent BioSolutions Inc. financial stats to get the full picture.
No, ER4 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 9, 2025, the company has 900 employees. See our rating of the largest employees — is Emergent BioSolutions Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Emergent BioSolutions Inc. EBITDA is ‪169.07 M‬ CHF, and current EBITDA margin is 5.14%. See more stats in Emergent BioSolutions Inc. financial statements.
Like other stocks, ER4 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Emergent BioSolutions Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Emergent BioSolutions Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Emergent BioSolutions Inc. stock shows the neutral signal. See more of Emergent BioSolutions Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.